David A. Siegel Cyma Bay Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $6.92 Million - $13.4 Million	-547,838 Reduced 82.01%	120,200 $2.84 Million
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $5.3 Million - $8.61 Million	-488,400 Reduced 42.23%	668,038 $9.96 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $1.93 Million - $2.83 Million	-258,400 Reduced 18.26%	1,156,438 $12.7 Million
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $5.95 Million - $9.7 Million	1,011,300 Added 250.61%	1,414,838 $12.3 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $76,314 - $148,599	23,700 Added 6.24%	403,538 $2.53 Million
Q3 2022 Nov 14, 2022	BUY	$2.77 - $4.25 $643,471 - $987,275	232,300 Added 157.45%	379,838 $1.33 Million
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $35,260 - $69,495	20,500 Added 16.14%	147,538 $435,000
Q1 2022 May 16, 2022	SELL	$2.77 - $3.64 $166,477 - $218,764	-60,100 Reduced 32.12%	127,038 $395,000
Q4 2021 Feb 14, 2022	SELL	$3.23 - $4.6 $635,018 - $904,359	-196,600 Reduced 51.23%	187,138 $633,000
Q3 2021 Nov 15, 2021	SELL	$3.47 - $4.42 $1.61 Million - $2.05 Million	-464,600 Reduced 54.77%	383,738 $1.4 Million
Q2 2021 Aug 16, 2021	SELL	$3.94 - $4.92 $1.85 Million - $2.31 Million	-469,600 Reduced 35.63%	848,338 $3.7 Million
Q1 2021 May 17, 2021	BUY	$4.23 - $6.55 $433,575 - $671,375	102,500 Added 8.43%	1,317,938 $5.98 Million
Q4 2020 Feb 16, 2021	BUY	$5.73 - $9.03 $4.63 Million - $7.29 Million	807,300 Added 197.8%	1,215,438 $6.98 Million
Q3 2020 Nov 16, 2020	BUY	$3.32 - $7.24 $117,860 - $257,020	35,500 Added 9.53%	408,138 $2.96 Million
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $28,764 - $86,700	20,400 Added 5.79%	372,638 $1.3 Million
Q1 2020 May 15, 2020	BUY	$1.25 - $2.02 $288,750 - $466,620	231,000 Added 190.53%	352,238 $521,000
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $161,246 - $718,941	121,238 New	121,238 $238,000
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $130,075 - $293,690	-21,500 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$8.16 - $13.42 $22,032 - $36,234	-2,700 Reduced 11.16%	21,500 $286,000
Q4 2018 Feb 14, 2019	SELL	$6.54 - $11.74 $91,560 - $164,360	-14,000 Reduced 36.65%	24,200 $190,000
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.52 $287,232 - $383,328	-26,400 Reduced 40.87%	38,200 $423,000
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $101,270 - $136,610	-9,500 Reduced 12.82%	64,600 $867,000
Q1 2018 May 15, 2018	BUY	$9.0 - $15.16 $535,500 - $902,020	59,500 Added 407.53%	74,100 $963,000
Q4 2017 Feb 14, 2018	BUY	$7.67 - $9.31 $6,136 - $7,448	800 Added 5.8%	14,600 $134,000
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $82,110 - $113,988	13,800	13,800 $111,000

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account